A kinome-centered CRISPR-Cas9 screen identifies activated BRAF to modulate enzalutamide resistance with potential therapeutic implications in BRAF-mutated prostate cancer

Resistance to drugs targeting the androgen receptor (AR) signaling axis remains an important challenge in the treatment of prostate cancer patients. Activation of alternative growth pathways is one mechanism used by cancer cells to proliferate despite treatment, conferring drug resistance. Through a...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Sci Rep
Päätekijät: Palit, Sander A. L., van Dorp, Jeroen, Vis, Daniel, Lieftink, Cor, Linder, Simon, Beijersbergen, Roderick, Bergman, Andries M., Zwart, Wilbert, van der Heijden, Michiel S.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2021
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC8249522/
https://ncbi.nlm.nih.gov/pubmed/34211036
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-021-93107-w
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia